Document:

<PAGE>
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

                                                                   EXHIBIT 10.13

                      FIRST AMENDMENT TO LICENSE AGREEMENT

      THIS FIRST AMENDMENT TO LICENSE AGREEMENT (the "AMENDMENT") is entered
into as of July 7, 2003 (the "AMENDMENT EFFECTIVE DATE"), between ALGORX
PHARMACEUTICALS, INC., a Delaware corporation ("ALGORX"), and POWDERJECT
RESEARCH LTD., an English corporation. ("POWDERJECT").

                                    RECITALS

      WHEREAS, AlgoRx and PowderJect entered into a License Agreement effective
as of March 22, 2002 (the "LICENSE AGREEMENT"), pursuant to which PowderJect has
granted to AlgoRx a license under certain intellectual property rights relating
to needleless powder injection, including, without limitation, the delivery of
products into the skin, and improvements thereof to discover, develop,
manufacture, and commercialize certain drug products;

      WHEREAS, pursuant to the License Agreement, PowderJect has the ability to
designate certain drug products as powderJect Named Products, and has exclusive
rights under AlgoRx's improvements to the needleless powder injection technology
licensed to AlgoRx by PowderJect to discover, develop, manufacture, and
commercialize such PowderJect Named Products;

      WHEREAS, the parties desire to amend the License Agreement to modify
AlgoRx's diligence obligations with respect to Cytokine Drugs and to clarify
AlgoRx's reporting obligations;

      NOW, THEREFORE, PowderJect and AlgoRx hereby agree that the License
Agreement shall be amended, effective as of the Amendment Effective Date, as
provided below:

      1.    All capitalized terms used but not otherwise defined herein shall
have the meanings ascribed to such terms in the License Agreement.

      2.    Section 2.9(b) of the License Agreement shall deleted in its
entirely and replaced with the following new Section 2.9(b):

      2.9(b) CYTOKINE DRUGS. AlgoRx agrees that AlgoRx and/or its Affiliates or
      licensees shall spend an aggregate of at least ****** on funding active
      research and development efforts on at least one Licensed Product that is
      a Cytokine Drug during the period extending from the Amendment Effective
      Date and the two (2) year anniversary of the Amendment Effective Date. For
      the avoidance of doubt, the ******* ****** aggregate research and
      development funding agreed herein expressly excludes any research and/or
      development funding, costs, liabilities or expenses or accrued prior to
      the Amendment Effective Date. Thereafter, AlgoRx agrees that AlgoRx and/or
      its Affiliates or Licensees shall spend an aggregate of at ****** *******
      on funding active research and development efforts on at least one
      Licensed Product that is a Cytokine Drug during each 12-month period
      commencing on the two (2) year anniversary of the Amendment Effective Date
      and expiring on the five (5) year anniversary of the Amendment Effective
      Date, If AlgoRx does not meet any of its funding obligations under this
      section, then thereafter the Cytokine Drugs shall be included within the
      definition of the term Selectable Products in Section 1.36 above.

<PAGE>

      3.    Section 2.9(c) of the License Agreement shall be deleted in its
entirety and replaced with the following new Section 2.9(c);

      2.9(c) REPORTS. AlgoRx shall keep PRL reasonably informed of AlgoRx's and
      its sublicensees' efforts under Sections 2.9(a) and 2.9(b) and upon PRL's
      request (no more often than once per year), shall provide PRL with a
      written report summarizing the status of such efforts.

      4.    Except as amended hereby, the Agreement shall remain in full force
and effect.

      5.    This Amendment may be executed in one or more counterparts, each of
which shall an original, and all of which shall constitute together the same
document.

      IN WITNESS WHEREOF, the parties have caused this Amendment to be executed:

ALGORX PHARMACEUTICALS INC.                POWDERJECT RESEARCH LIMITED

By: /s/ Gordon M. Saul                      By: /s/ C.S.W.SWINGLAND
    --------------------------------            --------------------------------
Name: Gordon M. Saul                        Name: C.S.W.SWINGLAND

Title: Vice President                       Title: DIRECTOR

                                       2<PAGE>
                                                                   EXHIBIT 10.14

                  ASSIGNMENT, ASSUMPTION AND CONSENT AGREEMENT

      THIS ASSIGNMENT, ASSUMPTION AND CONSENT AGREEMENT (this "Assignment") is
made as of May 14, 2004 by and among PowderMed Limited, an English company
("Assignee"), PowderJect Research Limited, an English company ("PRL"),
PowderJect Technologies Limited, an English company ("PTL," and each of PRL and
PTL an "Assignor" and collectively, the "Assignors"), AlgoRx Pharmaceuticals,
Inc., a Delaware corporation, and AlgoRx Technologies, Inc. (formerly PowderJect
Technologies, Inc.), a Delaware corporation.

                                    RECITALS

      WHEREAS, PRL, PTL and AlgoRx Pharmaceuticals, Inc. are parties to that
certain License Agreement dated as of March 22, 2002, and amended as of July
7, 2003 (the "License Agreement"), and PTL, AlgoRx Pharmaceuticals, Inc. and
AlgoRx Technologies, Inc. are parties to that certain Tools Agreement dated as
of March 22, 2002, and amended as of July 7, 2003 and by an undated extension
letter (the "Tools Agreement," and collectively with the License Agreement, the
"Agreements").

      WHEREAS, Assignors and Assignee are contemplating entering into a sale and
purchase agreement (the "Purchase Agreement") pursuant to which Assignors,
together with certain other parties, would agree to transfer to Assignee, and
Assignee would agree to acquire, all of the shares of PowderJect Vaccines
Limited and certain of the assets of Assignors and their affiliates, including
intellectual property that is the subject of the Agreements (the "Purchase").

      WHEREAS, pursuant to the Purchase Agreement, and subject to the terms and
conditions contained herein, Assignors wish to assign the Agreements to Assignee
and the Assignee wishes to have the Agreements assigned to it and to assume the
obligations of Assignors thereunder as set forth below.

      NOW, THEREFORE, for good and valuable consideration, the adequacy and
receipt of which are hereby acknowledged, the parties hereto agree as follows:

      1.    Assignment and Assumption. Conditional upon the occurrence of the
closing of the Purchase (the "Closing") and effective as of the closing date of
the Purchase Agreement (the "Closing Date"):

            (a) Assignors hereby irrevocably and unconditionally transfer,
assign and convey to the Assignee, all of Assignors' rights, title, interests
and benefits, and delegate to the Assignee all of Assignors' duties and
obligations, under the License Agreement, including all materials and
information in possession of Assignors related to the License Agreement, and the
Assignee hereby accepts and assumes the transfer, assignment, conveyance and
delegation of all rights, title, interests, benefits, duties and obligations of
Assignors under the License Agreement and hereby agrees to timely perform and
discharge all covenants and obligations of Assignors under the License
Agreement; provided, however, that Assignors do not transfer, assign or convey
to Assignee, and PRL hereby expressly retains, all rights, interests and
benefits of PRL under Article 3 of the License Agreement, including, but not
limited to, the right to receive from

<PAGE>

AlgoRx Pharmaceuticals, Inc. royalties under Sections 3.1 and 3.2 of the License
Agreement. PRL shall have the right to exercise and enforce against AlgoRx
Pharmaceuticals, Inc. directly all such retained rights, interests and benefits.
Notwithstanding anything contained herein to the contrary, in order to ensure
that PRL continues to receive and enjoy its retained rights, interests and
benefits under Article 3 of the License Agreement, from and after the date
hereof, Assignee and AlgoRx Pharmaceuticals, Inc. shall have no right to amend,
change, waive, discharge or otherwise modify the License Agreement, or any term
or condition thereof, to the extent that such amendment, change, waiver,
discharge or modification would diminish or otherwise adversely affect PRL's
rights, interests or benefits under Article 3 thereof, including, without
limitation, the amount or timing of royalties due to PRL, unless and until PRL
grants its consent thereto in writing. No attempt by Assignee or AlgoRx
Pharmaceuticals, Inc. to amend, change, waive, discharge or otherwise modify the
License Agreement in violation of this Section l(a) shall have any force or
effect. For the avoidance of doubt, except as provided in Section 4 hereof,
nothing contained herein shall alter or affect any right of Assignee or AlgoRx
Pharmaceuticals, Inc. to seek any right or remedy in law or equity under the
License Agreement, including, without limitation, terminating the License
Agreement or setting-off amounts otherwise due and owing under the License
Agreement, in each case on the terms and subject to the conditions of Article 6
of the License Agreement.

            (b) PTL hereby irrevocably and unconditionally transfers, assigns
and conveys to the Assignee, all of its rights, title, interests and benefits,
and delegates to the Assignee all of PTL's duties and obligations, under the
Tools Agreement, including all materials and information in possession of PTL
related to the Tools Agreement, and the Assignee hereby accepts and assumes the
transfer, assignment, conveyance, and delegation of all rights, title,
interests, benefits, duties and obligations of PTL under the Tools Agreement and
hereby agrees to timely perform and discharge all covenants and obligations of
PTL under the Tools Agreements.

            (c) Notwithstanding any of the foregoing, nothing in this Assignment
shall affect or prejudice any claim or demand whatsoever which an Assignor may
have against AlgoRx Pharmaceuticals, Inc. and/or AlgoRx Technologies, Inc. in
relation to the Agreements and arising out of matters prior to the Closing Date.

      2.    Right of Reimbursement. Notwithstanding any of the foregoing, each
of PRL and AlgoRx Pharmaceuticals, Inc. shall retain its rights of reimbursement
from the other party pursuant to Sections 4.2(c) or 4.3(c) of the License
Agreement, as the case may be, for Patent Expenses (as defined in the License
Agreement) incurred prior to the Closing Date. PRL and AlgoRx Pharmaceuticals,
Inc. hereby agree to pay to each other any amounts due from one party to the
other under Sections 4.2(c) or 4.3(c) of the License Agreement no later than
sixty (60) days after the Closing Date.

      3.    Patent Prosecution and Enforcement. Assignors, Assignee and AlgoRx
Pharmaceuticals, Inc. acknowledge and agree that, notwithstanding the assignment
of the License Agreement pursuant to Section 1 hereof, AlgoRx Pharmaceuticals,
Inc. shall retain any and all of its rights under License Agreement in respect
of the prosecution and enforcement of patent applications and patents, in each
case on the terms and subject to the conditions of the

                                       2

<PAGE>

License Agreement, which rights shall be enforceable on or after the Closing
Date solely against Assignee (except to the extent otherwise provided in Section
2 hereof).

      4.    Consent and Release. In accordance with Section 9.6 of the License
Agreement and Section 9.3 of the Tools Agreement, AlgoRx Pharmaceuticals, Inc.
and AlgoRx Technologies, Inc. each hereby consents to the assignment of the
Agreements as provided herein, conditional upon the occurrence of the Closing
and effective as of the Closing Date. AlgoRx Pharmaceuticals, Inc. and AlgoRx
Technologies, Inc. each hereby releases Assignors (and each other company in the
PowderJect Group (as defined in the License Agreement)) from any further
obligation or liability under the Agreements, including, without limitation,
under Section 9.15 of the License Agreement, conditional upon the occurrence of
the Closing and effective as of the Closing Date; provided, however,
notwithstanding the foregoing, PRL shall not be released from any liability or
obligation under (i) Article 7 of the License Agreement, to the extent such
liability or obligation relates to or arises from any act or omission of PRL or
any of its officers, directors, employees or agents prior to, on or after the
Closing Date, and (ii) Section 8.3 of the License Agreement.

      5.    AlgoRx Claims. Notwithstanding anything to the contrary contained
herein, nothing in this Assignment (i) shall affect or prejudice any claim or
demand whatsoever which AlgoRx Pharmaceuticals, Inc. or AlgoRx Technologies,
Inc. may have against Assignors (or any other company in the PowderJect Group)
in relation to the Agreements and arising out of matters prior to the Closing
Date or against the Assignees arising out of matters on and after the Closing
Date or (ii) except as provided in Section 4 hereof, shall limit or restrict
AlgoRx Pharmaceuticals, Inc. or AlgoRx Technologies, Inc. from exercising any
right or remedy under the Agreements; provided, however, that any action brought
by AlgoRx Pharmaceuticals, Inc. or AlgoRx Technologies, Inc. in relation to the
Agreements in respect of any claim or demand arising out of matters prior to the
Closing Date shall be brought against Assignors (or the applicable company in
the PowderJect Group, as the case may be) only and not the Assignee.

      6. Representations and Covenants. Assignors represent and warrant to, and
covenant with, AlgoRx Pharmaceuticals, Inc. as follows:

            (i) As far as Assignors are aware, effective as of the Closing Date,
      Assignors shall sell or assign to Assignee under the Purchase Agreement,
      all assets owned by Assignors that are necessary for Assignee to perform
      on a timely basis all of its obligations under the License Agreement,
      including all such assets comprising PowderJect Technology and PowderJect
      Improvements as of the Closing Date; and

            (ii) (A) Assignors acknowledge that nothing contained herein shall
      constitute an assignment to Assignee of the Supply Agreement, (B)
      Assignors acknowledge that gas cylinders supplied by PTL to AlgoRx
      Pharmaceuticals Inc. under the Supply Agreement are critical to the
      business of AlgoRx Pharmaceuticals, Inc. which has no alternative source
      of supply, (C) PTL agrees that it will carry out its obligations under the
      Supply Agreement in accordance with the terms of the Supply Agreement, and
      (D) Assignors acknowledge that AlgoRx Pharmaceuticals, Inc. is relying on
      this acknowledgement and covenant in consenting to this Assignment; and

                                       3

<PAGE>

            (iii) The Assignors will notify AlgoRx Pharmaceuticals, Inc. in
      writing via e-mail (rmburch@algorx.com with a copy to sdavis@hewm.com)
      promptly following the Closing that the Closing has occurred.

      7.    Successors and Assigns. This Assignment shall inure to the benefit
of and be binding upon the parties hereto and their respective legal
representatives, successors and permitted assigns.

      8.    Governing Law. This Assignment shall be governed and construed in
accordance with the laws of the State of Delaware, to the extent that it relates
to or is otherwise construed in connection with the Tools Agreement, and shall
be governed and construed in accordance with the laws of the State of
California, to the extent that it relates to or is otherwise construed in
connection with the License Agreement, in each case excluding any conflicts or
choice of law rule or principle that might otherwise refer construction or
interpretation of this Assignment to the substantive law of another
jurisdiction.

      9.    Amendments; Waivers, Etc. Neither this Assignment nor any term
hereof may be amended, changed, waived, discharged or terminated other than by
an instrument in writing, signed by the party against which enforcement of such
amendment, change, waiver, discharge or termination is sought.

      10.   Counterparts. This Assignment may be executed in two or more
counterparts, each of which shall be deemed to be an original, and all of which
together shall constitute one and the same instrument.

                            [SIGNATURE PAGE FOLLOWS.]

                                       4

<PAGE>

      IN WITNESS WHEREOF, each of the parties hereto has caused this Assignment
to be duly executed and delivered as of the day and year first above written.

                                          Assignors:

                                          POWDERJECT RESEARCH LIMITED

                                          By: /s/ ILLEGIBLE
                                              ----------------------------------

                                          POWDERJECT TECHNOLOGIES LIMITED

                                          By: /s/ ILLEGIBLE
                                              ----------------------------------

                                          Assignee:

                                          POWDERMED LIMITED

                                          By: /s/ ILLEGIBLE
                                              ----------------------------------

                                          Counterparties:

                                          ALGORX PHARMACEUTICALS, INC.

                                          By: /s/ Ronald M. Burch
                                              ----------------------------------

                                          ALGORX TECHNOLOGIES, INC.

                                          By: /s/ Ronald M. Burch
                                              ----------------------------------

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]